ALDURAZYME
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALDURAZYME (ALDURAZYME).
ALDURAZYME (laronidase) is a recombinant form of human α-L-iduronidase, an enzyme that hydrolyzes terminal α-L-iduronic acid residues in glycosaminoglycans (GAGs) such as dermatan sulfate and heparan sulfate. It replaces the deficient enzyme in patients with mucopolysaccharidosis I (MPS I), reducing lysosomal accumulation of GAGs.
| Metabolism | Laronidase is a recombinant protein. It is degraded via catabolic pathways into small peptides and amino acids. No specific metabolic enzymes are involved; clearance is primarily through reticuloendothelial system. |
| Excretion | Renal: negligible; primarily catabolism via peptide hydrolysis; no significant biliary/fecal elimination |
| Half-life | Terminal half-life: 6–10 minutes (rapid clearance from plasma due to cellular uptake via mannose-6-phosphate receptors); clinical context: clearance is saturable, leading to longer effective half-life at therapeutic doses |
| Protein binding | Not reported; protein binding is negligible due to rapid cellular uptake |
| Volume of Distribution | Vd: 0.42–0.60 L/kg; indicates distribution primarily into extracellular fluid and tissues with high mannose-6-phosphate receptor expression (e.g., liver, spleen, kidney) |
| Bioavailability | Intravenous: 100% (only route of administration); no oral bioavailability due to protein degradation and poor absorption |
| Onset of Action | Intravenous: clinical improvement in urinary glycosaminoglycan (GAG) excretion observed within 2–4 weeks of weekly infusions; hepatic and spleen size reduction begins by 3–6 months |
| Duration of Action | Duration of enzyme activity: approximately 1 week; weekly dosing required to maintain clinical effect; sustained reductions in GAG levels persist with continued therapy |
0.58 mg/kg administered intravenously once weekly.
| Dosage form | VIAL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No specific recommendations; clinical experience limited. |
| Pediatric use | Same as adult, 0.58 mg/kg IV once weekly. |
| Geriatric use | No specific dose adjustments; clinical experience limited. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALDURAZYME (ALDURAZYME).
| Breastfeeding | Unknown if laronidase is excreted in human milk. M/P ratio not determined. Caution advised; consider developmental benefits of breastfeeding versus mother's clinical need. |
| Teratogenic Risk | Aldurazyme (laronidase) is an enzyme replacement therapy for mucopolysaccharidosis I (MPS I). Limited human data; animal studies show no evidence of teratogenicity in mice at doses up to 3.5 mg/kg/day (approximately 1.3 times the human weekly dose). Risk cannot be excluded; use only if clearly needed. |
| Fetal Monitoring |
■ FDA Black Box Warning
No black box warning.
| Serious Effects |
["History of life-threatening hypersensitivity reaction to laronidase or any excipients."]
| Precautions | ["Infusion reactions: Risk of anaphylaxis, severe allergic reactions. Premedicate with antihistamines/antipyretics; monitor during infusion.","Hypersensitivity: Including urticaria, respiratory distress, hypotension. Discontinue if severe reaction occurs.","Acute respiratory compromise: Patients with underlying airway obstruction may be at increased risk during infusion.","Immunogenicity: Development of anti-laronidase antibodies may affect efficacy or increase infusion reactions.","Not intended for central nervous system manifestations of MPS I (e.g., cognitive decline) as it does not cross the blood-brain barrier."] |
| Food/Dietary | No known food interactions. Aldurazyme is administered intravenously and does not have dietary restrictions. |
Loading safety data…
| Monitor pregnant women for hypersensitivity reactions including anaphylaxis, infusion-related reactions (fever, chills, rash). Fetal monitoring via ultrasound for growth and anomalies if exposure occurs. |
| Fertility Effects | No human data on fertility. In animal studies, no adverse effects on male or female fertility in mice at doses up to 3.5 mg/kg/day. |
| Clinical Pearls | Aldurazyme (laronidase) is indicated for patients with Hurler syndrome (MPS I) to improve respiratory function and reduce glycosaminoglycan accumulation. Administer as an IV infusion over 3-4 hours, starting at a rate of 10 mcg/kg/hr and increasing as tolerated. Premedicate with antihistamines and antipyretics due to risk of infusion-related reactions. Monitor for anaphylaxis; have epinephrine available. Do not administer to patients with severe airway obstruction without careful assessment. |
| Patient Advice | Aldurazyme is given as an IV infusion every week to replace the missing enzyme. · You may receive medications before each infusion to reduce the risk of allergic reactions. · Infusion reactions (fever, chills, rash) are common; notify your doctor immediately if they occur. · Report any signs of anaphylaxis (difficulty breathing, swelling of face or throat, hives). · Treatment is lifelong and does not reverse existing damage but slows disease progression. |